Developer docs
API playgroundTry for free, no card

Search company profiles

Phase Holographic Imaging

Full company profile

uuid00021z2

Namestring
Phase Holographic Imaging
Legal namestring
Phase Holographic Imaging PHI AB
Websiteurl
phiab.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Phase Holographic Imaging PHI AB is a Swedish medical technology company headquartered in Lund that developed and commercialized the HoloMonitor line of cell imaging systems. The company's core technology is Quantitative Phase Imaging (QPI), a digital holography approach that images living cells label-free using low-energy light, eliminating stains, labels, and additives that can interfere with cellular behavior. The HoloMonitor M4 hardware is a compact incubator-based instrument designed to run 24/7 inside standard cell culture incubators, paired with the App Suite software that automates cell segmentation, tracks individual cells, and extracts more than 30 morphological parameters per cell. A December 2025 product refresh, HoloMonitor Next Generation, was the platform's most recent iteration, and the company filed a HoloOocyte trademark in October 2025 to extend the technology into veterinary IVF and livestock embryo assessment.

The company served academic and life science research institutions, pharmaceutical and biotech drug discovery groups, and (newly) the veterinary IVF market. Customers named in the source material include Novo Nordisk, University of Michigan-Dearborn, Malmö University, Lund University, Stanford University, and INSA Lyon. PHI monetized through one-time/quoted hardware sales of the HoloMonitor instrument plus subscription-based App Suite software, with add-on revenue from a Fluorescence Module and HoloLids accessories. Go-to-market combined direct enterprise sales in Sweden, the US, and the UK with a distributor network spanning 40+ countries across Europe, the Americas, Asia-Pacific, and the Middle East. Scientific credibility was driven by more than 300 peer-reviewed publications citing HoloMonitor.

In December 2024, PHI completed a SEK 64.3 million rights issue with Altium SA as underwriter, raising Altium's stake to 41.6%. Through 2025 PHI reported declining sales and increased losses alongside its next-generation product transition and a board change. In January 2026, Altium acquired PHI's assets and intellectual property including the HoloMonitor product line following PHI's announcement of intent to file for bankruptcy.

Short descriptiontext

Swedish medical technology company that develops and sells HoloMonitor, a label-free live cell imaging system based on quantitative phase imaging and digital holography, serving academic researchers, pharmaceutical drug discovery groups, and veterinary IVF applications globally.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLund, Sweden
HQ citystring
Lund
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
live cell imaging, quantitative phase imaging, digital holography microscopy, label-free cell analysis, cell culture instruments
Industry3 codes
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Optical Instruments & Lenses3827
Product category
Live Cell Imaging Instruments
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1HoloMonitor Hardware Systems
TypeHardware Sales
Description

Sale of HoloMonitor M4 live cell imaging hardware including base unit, motorized XYZ stage, and laser components. The system is sold as a complete instrument for laboratory installation.

phiab.com
2App Suite Software Licenses
TypeSubscription Recurring
Description

Software licensing for HoloMonitor App Suite providing cell imaging analysis capabilities and assay applications. Includes cell morphology, proliferation, motility, dose response, and single-cell tracking assays.

phiab.com
3Fluorescence Add-on Unit
TypeHardware Sales
Description

Optional fluorescence module that integrates with the base holographic system to add green fluorescence dimension to label-free data.

phiab.com
4HoloLids and Accessories
TypeHardware Sales
Description

Specialized accessories including HoloLids for optimal imaging conditions, and consumables for various culture vessel formats.

phiab.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Pricing details2 tiers
1HoloMonitor M4 System - Complete live cell imaging system with base unit, motorized stage, and software
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Quote-based pricing not publicly disclosed. Website describes system as 'affordable for any cell lab'.

phiab.com
2App Suite Software - Assay applications and analysis software
ModelSubscriptionBilling cadenceAnnual
Notes

Software licensing with annual subscription model. Includes assay updates and technical support.

phiab.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1HoloMonitor
Description

Live cell imaging system based on digital holography/QPI technology for non-invasive cell analysis

phiab.com
+4 more records
Core offering1 text field

Phase Holographic Imaging develops, manufactures, and sells the HoloMonitor live cell imaging system—an incubator-based microscope that uses proprietary Quantitative Phase Imaging (QPI) and digital holography to capture non-invasive, label-free 3D images of living cells. The HoloMonitor hardware is paired with the App Suite cell imaging software and a portfolio of automated assays (morphology, motility, proliferation, single-cell tracking, wound healing, dose response, cell counting, QC) sold to cancer researchers, stem cell researchers, and pharmaceutical drug discovery labs across 40+ countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 30 unique cellular parameters measured per cell including cell area, thickness, volume, and migration speed
+3 more records
Product overview1 text field

Phase Holographic Imaging (PHI) offers the HoloMonitor system, a comprehensive live cell analysis platform centered on quantitative phase imaging (QPI) and digital holography technology. The core offering consists of the HoloMonitor M4 hardware unit (an incubator-based microscope) combined with the App Suite software platform. The system provides multiple assay modules including Cell Morphology, Single Cell Tracking, Kinetic Cell Motility, Kinetic Cell Proliferation, Cell Counter, Cell QC, Wound Healing, and Kinetic Dose Response assays—all running on the unified App Suite software. Optional add-ons include a Fluorescence unit and HoloLids accessories. The company recently launched the HoloMonitor Next Generation platform and expanded into veterinary IVF applications with the HoloOocyte product line.

Product and service1 record
1HoloMonitor M4
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1National Institute on Aging
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partnership for applications of holographic imaging technology in aging research and related biomedical studies.

phiab.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partnership for development and application of live cell imaging technologies in cell biology research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partnership applying HoloMonitor technology to cancer research applications including cancer cell behavior and drug response studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partnership for cell imaging and analysis applications in biomedical research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partnership applying holographic imaging technology to cardiovascular and neurological disease research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Regional research partnership supporting cancer research with HoloMonitor live cell imaging technology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic partnership for cell biology research, drug effects studies, and technology development. Professor Anette Gjörloff Wingren conducts research using HoloMonitor.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic research partnership in cell imaging and analysis for various biomedical applications.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Switzerland-based Nanolive offers label-free live cell imaging using holo-tomography (a digital holography technique), making it the closest technology peer to PHI's QPI-based HoloMonitor. Both compete for academic and pharma researchers seeking non-invasive, stain-free kinetic cell analysis.

TypeBroad incumbent
Description

Agilent's BioTek Cytation and Lionheart cell imaging multimode readers are widely deployed in pharma and academic labs for live cell kinetic imaging. They overlap with HoloMonitor in morphology, proliferation, and wound healing assays but with broader plate-reader integration.

TypeEmerging player
Description

CytoSMART offers compact, incubator-friendly live cell imaging devices for routine cell culture monitoring. It overlaps with HoloMonitor's miniaturized form-factor positioning but with a focus on simpler cell-counting and confluence workflows rather than deep holographic morphology.

TypeBroad incumbent
Description

Sartorius's Incucyte system is the dominant live cell imaging platform for kinetic, incubator-based assays in pharma and academic labs. It overlaps directly with HoloMonitor's positioning for non-invasive, time-lapse proliferation, motility, and cytotoxicity workflows but with a far broader assay menu and installed base.

5Carl Zeiss Microscopy
TypeBroad incumbent
Description

Zeiss offers a broad range of advanced light and confocal microscopy systems used in cell biology research. While not directly incubator-based, Zeiss competes for the same research imaging budgets and is expanding label-free and AI-driven imaging capabilities relevant to PHI's customer base.

TypeEmerging player
Description

Etaluma manufactures compact, low-cost incubator microscopes for live cell imaging. It competes for budget-conscious academic and pharma labs evaluating affordable alternatives to higher-priced HoloMonitor and Incucyte systems.

TypeBroad incumbent
Description

Molecular Devices provides high-content imaging and analysis systems (ImageXpress) widely used in pharma drug discovery. It competes for the same pharmaceutical and academic screening budgets that HoloMonitor targets, particularly for cell morphology and kinetic assays.

TypeBroad incumbent
Description

Revvity supplies high-content imaging and screening instruments used in pharma drug discovery and cell biology. Its Opera and Cell::Explorer systems overlap with HoloMonitor's high-content, kinetic screening use cases for pharmaceutical R&D customers.

TypeBroad incumbent
Description

Leica provides high-end research microscopy systems widely used in cell biology and cancer research. It competes for advanced imaging budgets alongside HoloMonitor's QPI value proposition, particularly in academic and pharma core facilities.

TypeBroad incumbent
Description

Thermo Fisher offers a broad portfolio of cell imaging instruments and high-content screening systems across life sciences. Its EVOS and HCS platforms compete with HoloMonitor in cancer research, stem cell workflows, and pharma drug discovery use cases.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Phase Holographic Imaging

Live Cell Imaging Instrumentsphiab.com

Swedish medical technology company that develops and sells HoloMonitor, a label-free live cell imaging system based on quantitative phase imaging and digital holography, serving academic researchers, pharmaceutical drug discovery groups, and veterinary IVF applications globally.

What Phase Holographic Imaging does

Phase Holographic Imaging PHI AB is a Swedish medical technology company headquartered in Lund that developed and commercialized the HoloMonitor line of cell imaging systems. The company's core technology is Quantitative Phase Imaging (QPI), a digital holography approach that images living cells label-free using low-energy light, eliminating stains, labels, and additives that can interfere with cellular behavior. The HoloMonitor M4 hardware is a compact incubator-based instrument designed to run 24/7 inside standard cell culture incubators, paired with the App Suite software that automates cell segmentation, tracks individual cells, and extracts more than 30 morphological parameters per cell. A December 2025 product refresh, HoloMonitor Next Generation, was the platform's most recent iteration, and the company filed a HoloOocyte trademark in October 2025 to extend the technology into veterinary IVF and livestock embryo assessment.

The company served academic and life science research institutions, pharmaceutical and biotech drug discovery groups, and (newly) the veterinary IVF market. Customers named in the source material include Novo Nordisk, University of Michigan-Dearborn, Malmö University, Lund University, Stanford University, and INSA Lyon. PHI monetized through one-time/quoted hardware sales of the HoloMonitor instrument plus subscription-based App Suite software, with add-on revenue from a Fluorescence Module and HoloLids accessories. Go-to-market combined direct enterprise sales in Sweden, the US, and the UK with a distributor network spanning 40+ countries across Europe, the Americas, Asia-Pacific, and the Middle East. Scientific credibility was driven by more than 300 peer-reviewed publications citing HoloMonitor.

In December 2024, PHI completed a SEK 64.3 million rights issue with Altium SA as underwriter, raising Altium's stake to 41.6%. Through 2025 PHI reported declining sales and increased losses alongside its next-generation product transition and a board change. In January 2026, Altium acquired PHI's assets and intellectual property including the HoloMonitor product line following PHI's announcement of intent to file for bankruptcy.

Phase Holographic Imaging firmographics

Firmographics
Name
Phase Holographic Imaging
Legal name
Phase Holographic Imaging PHI AB
Website
https://phiab.com
Company type
Private
Founded year
2012
Operating status
Acquired
Headcount range
1–10 employees
Short description
Swedish medical technology company that develops and sells HoloMonitor, a label-free live cell imaging system based on quantitative phase imaging and digital holography, serving academic researchers, pharmaceutical drug discovery groups, and veterinary IVF applications globally.
Ownership category
akta.pro rank

Phase Holographic Imaging industry classification

Industry
Product category
Live Cell Imaging Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Laboratory Analytical Instruments (3826), Optical Instruments & Lenses (3827)
akta.pro industry
PRIMARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Live cell imaging
  • Quantitative phase imaging
  • Digital holography microscopy
  • Label-free cell analysis
  • Cell culture instruments

Where Phase Holographic Imaging is headquartered

Location

Headquarters

HQ city
Lund
HQ country
Sweden
HQ region
Europe

Offices4 records

Markets served

Phase Holographic Imaging business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. HoloMonitor Hardware Systems: Sale of HoloMonitor M4 live cell imaging hardware including base unit, motorized XYZ stage, and laser components. The system is sold as a complete instrument for laboratory installation.
  2. App Suite Software Licenses: Software licensing for HoloMonitor App Suite providing cell imaging analysis capabilities and assay applications. Includes cell morphology, proliferation, motility, dose response, and single-cell tracking assays.
  3. Fluorescence Add-on Unit: Optional fluorescence module that integrates with the base holographic system to add green fluorescence dimension to label-free data.
  4. HoloLids and Accessories: Specialized accessories including HoloLids for optimal imaging conditions, and consumables for various culture vessel formats.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractHoloMonitor M4 System - Complete live cell imaging system with base unit, motorized stage, and software
SubscriptionAnnualApp Suite Software - Assay applications and analysis software

Go-to-market motion2 records

Distribution channels2 records

Marketing channels7 records

Phase Holographic Imaging product offering

Product offering

Core offering

Phase Holographic Imaging develops, manufactures, and sells the HoloMonitor live cell imaging system—an incubator-based microscope that uses proprietary Quantitative Phase Imaging (QPI) and digital holography to capture non-invasive, label-free 3D images of living cells. The HoloMonitor hardware is paired with the App Suite cell imaging software and a portfolio of automated assays (morphology, motility, proliferation, single-cell tracking, wound healing, dose response, cell counting, QC) sold to cancer researchers, stem cell researchers, and pharmaceutical drug discovery labs across 40+ countries.

Product overview

Phase Holographic Imaging (PHI) offers the HoloMonitor system, a comprehensive live cell analysis platform centered on quantitative phase imaging (QPI) and digital holography technology. The core offering consists of the HoloMonitor M4 hardware unit (an incubator-based microscope) combined with the App Suite software platform. The system provides multiple assay modules including Cell Morphology, Single Cell Tracking, Kinetic Cell Motility, Kinetic Cell Proliferation, Cell Counter, Cell QC, Wound Healing, and Kinetic Dose Response assays—all running on the unified App Suite software. Optional add-ons include a Fluorescence unit and HoloLids accessories. The company recently launched the HoloMonitor Next Generation platform and expanded into veterinary IVF applications with the HoloOocyte product line.

Differentiator

Problem solved

Functional benefit

Brands

  • HoloMonitor: Live cell imaging system based on digital holography/QPI technology for non-invasive cell analysis
  • HoloOocyte
  • HoloMonitor Next Generation
  • App Suite
  • HoloLids

Products and services

  • HoloMonitor M4

Quantifiable outcome

  • Over 30 unique cellular parameters measured per cell including cell area, thickness, volume, and migration speed
  • +3 more outcomes

Companies that use Phase Holographic Imaging

Customer profile

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Phase Holographic Imaging technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Phase Holographic Imaging partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core.

  • National Institute on AgingcoreStrategic or Co-development PartnerResearch partnership for applications of holographic imaging technology in aging research and related biomedical studies.
  • Northeastern UniversitycoreStrategic or Co-development PartnerAcademic research partnership for development and application of live cell imaging technologies in cell biology research.
  • Huntsman Cancer InstitutecoreStrategic or Co-development PartnerResearch partnership applying HoloMonitor technology to cancer research applications including cancer cell behavior and drug response studies.
  • UCSF (University of California San Francisco)coreStrategic or Co-development PartnerAcademic research partnership for cell imaging and analysis applications in biomedical research.
  • Gladstone InstitutescoreStrategic or Co-development PartnerResearch partnership applying holographic imaging technology to cardiovascular and neurological disease research.
  • Lund University Cancer CentrecoreStrategic or Co-development PartnerRegional research partnership supporting cancer research with HoloMonitor live cell imaging technology.
  • Malmö UniversitycoreStrategic or Co-development PartnerAcademic partnership for cell biology research, drug effects studies, and technology development. Professor Anette Gjörloff Wingren conducts research using HoloMonitor.
  • Uppsala UniversitycoreStrategic or Co-development PartnerAcademic research partnership in cell imaging and analysis for various biomedical applications.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Phase Holographic Imaging competitors and assessment

Company assessment

Direct peers

  • Nanolive: Switzerland-based Nanolive offers label-free live cell imaging using holo-tomography (a digital holography technique), making it the closest technology peer to PHI's QPI-based HoloMonitor. Both compete for academic and pharma researchers seeking non-invasive, stain-free kinetic cell analysis.

Broad incumbents

  • Agilent Technologies (BioTek Cytation / Lionheart): Agilent's BioTek Cytation and Lionheart cell imaging multimode readers are widely deployed in pharma and academic labs for live cell kinetic imaging. They overlap with HoloMonitor in morphology, proliferation, and wound healing assays but with broader plate-reader integration.
  • Sartorius (Essen BioScience / Incucyte): Sartorius's Incucyte system is the dominant live cell imaging platform for kinetic, incubator-based assays in pharma and academic labs. It overlaps directly with HoloMonitor's positioning for non-invasive, time-lapse proliferation, motility, and cytotoxicity workflows but with a far broader assay menu and installed base.
  • Carl Zeiss Microscopy: Zeiss offers a broad range of advanced light and confocal microscopy systems used in cell biology research. While not directly incubator-based, Zeiss competes for the same research imaging budgets and is expanding label-free and AI-driven imaging capabilities relevant to PHI's customer base.
  • Molecular Devices (MetaMorph / ImageXpress): Molecular Devices provides high-content imaging and analysis systems (ImageXpress) widely used in pharma drug discovery. It competes for the same pharmaceutical and academic screening budgets that HoloMonitor targets, particularly for cell morphology and kinetic assays.
  • Revvity (formerly PerkinElmer): Revvity supplies high-content imaging and screening instruments used in pharma drug discovery and cell biology. Its Opera and Cell::Explorer systems overlap with HoloMonitor's high-content, kinetic screening use cases for pharmaceutical R&D customers.
  • Leica Microsystems (Danaher): Leica provides high-end research microscopy systems widely used in cell biology and cancer research. It competes for advanced imaging budgets alongside HoloMonitor's QPI value proposition, particularly in academic and pharma core facilities.
  • Thermo Fisher Scientific (EVOS / CellInsight / HCS platforms): Thermo Fisher offers a broad portfolio of cell imaging instruments and high-content screening systems across life sciences. Its EVOS and HCS platforms compete with HoloMonitor in cancer research, stem cell workflows, and pharma drug discovery use cases.

Emerging players

  • CytoSMART (Corning): CytoSMART offers compact, incubator-friendly live cell imaging devices for routine cell culture monitoring. It overlaps with HoloMonitor's miniaturized form-factor positioning but with a focus on simpler cell-counting and confluence workflows rather than deep holographic morphology.
  • Etaluma: Etaluma manufactures compact, low-cost incubator microscopes for live cell imaging. It competes for budget-conscious academic and pharma labs evaluating affordable alternatives to higher-priced HoloMonitor and Incucyte systems.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Phase Holographic Imaging social profiles

Digital presence

Phase Holographic Imaging financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Phase Holographic Imaging leadership team

Management profile

Number of profiles

Profiles5 records

Phase Holographic Imaging subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Phase Holographic Imaging funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Phase Holographic Imaging M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phase Holographic Imaging

What does Phase Holographic Imaging do?

Phase Holographic Imaging develops, manufactures, and sells the HoloMonitor live cell imaging system—an incubator-based microscope that uses proprietary Quantitative Phase Imaging (QPI) and digital holography to capture non-invasive, label-free 3D images of living cells. The HoloMonitor hardware is paired with the App Suite cell imaging software and a portfolio of automated assays (morphology, motility, proliferation, single-cell tracking, wound healing, dose response, cell counting, QC) sold to cancer researchers, stem cell researchers, and pharmaceutical drug discovery labs across 40+ countries.

Is Phase Holographic Imaging a public or private company?

Phase Holographic Imaging is a private company. It is classified as public and is currently acquired.

When was Phase Holographic Imaging founded?

Phase Holographic Imaging was founded in 2012. It employs 1 to 10 people.

Where is Phase Holographic Imaging based?

Phase Holographic Imaging is headquartered in Lund, Sweden, in the Europe region.

How does Phase Holographic Imaging make money?

Four revenue lines are on record. HoloMonitor Hardware Systems are the primary driver. The others are app Suite Software Licenses, fluorescence Add-on Unit and holoLids and Accessories.

Who are Phase Holographic Imaging's main competitors?

Nanolive is listed as a direct peer. Broad incumbents are Agilent Technologies (BioTek Cytation / Lionheart), Sartorius (Essen BioScience / Incucyte), Carl Zeiss Microscopy, Molecular Devices (MetaMorph / ImageXpress), Revvity (formerly PerkinElmer), Leica Microsystems (Danaher) and Thermo Fisher Scientific (EVOS / CellInsight / HCS platforms). Emerging players are CytoSMART (Corning) and Etaluma.

Does Phase Holographic Imaging have an API?

No public API is recorded for Phase Holographic Imaging.

What industry is Phase Holographic Imaging in?

Phase Holographic Imaging's product category is Live Cell Imaging Instruments. Its primary akta.pro industry code is HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments, with a secondary code of HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
news.cision.comPhase Holographic Imaging Announces Board ChangePhase Holographic Imaging announced that Mats Lundwall has resigned from its Board of Directors at his own request, effective immediately. The board expressed gratitude for his contributions and wished him future success. The disclosure was submitted for publication on December 30, 2025 under EU Market Abuse Regulation requirements.news.cision.comInterim Report 2 2025/26Phase Holographic Imaging (PHI) reported significantly reduced second-quarter fiscal 2025/26 results with net sales of 306 KSEK, down from 2,977 KSEK year-over-year, alongside an operating loss of -5,445 KSEK and net loss of -7,761 KSEK. The company attributed the sales decline to the ongoing transition of sales operations from Altium back to PHI and customer anticipation of the newly launched HoloMonitor Next Generation (released December 17). PHI also announced its expansion into the veterinary IVF market for livestock, filing a trademark for "HoloOocyte" to assess oocytes and embryos using its QPI technology, while warning that current capital resources are approaching their limits.news.cision.comPHI sets sights on IVF applications in livestockPHI (Phase Holographic Imaging PHI AB), a Swedish medical technology company, announced its strategic expansion into in vitro fertilization applications for livestock, leveraging its Quantitative Phase Imaging technology to improve assessment of oocytes and embryos in cows and horses. The company has filed a trademark application for "HoloOocyte" and plans to launch its next-generation HoloMonitor later this year, aiming to make livestock IVF more consistent, efficient, and scalable. The global bovine IVF market is projected to grow at 7.9% CAGR to nearly USD 2.9 billion by 2033, with PHI targeting this expanding sector as part of its long-term strategy to move from pre-clinical research into applied and clinical markets.TradingViewPHI provides an update regarding the development progress of the new generation of HoloMonitor®PHI AB updated its new-generation HoloMonitor, scheduled for launch before end of 2025, with AI integration and automated cell segmentation. The system targets clinical and pharmaceutical markets, including cell therapy quality control, and is expected to shorten sales cycles to 2-3 months.news.cision.comPHI announces outcome of rights issuePhase Holographic Imaging (PHI) completed a rights issue raising approximately SEK 64.3 million, with the subscription fully covered by initial investor commitments and activated underwriting agreements. Altium SA increased its stake to approximately 41.6 percent of votes and capital, triggering a lock-up agreement for six months. The company intends to use the proceeds to strengthen its financial position and accelerate growth in its medical technology operations.news.cision.comPHI secures a loan facility of in total SEK 7 millionPhase Holographic Imaging (PHI) has secured a loan facility of SEK 7 million from Bizcap AB, drawing an initial tranche of SEK 4.5 million to support working capital. The financing arrangement carries a setup fee of 5 percent and an interest rate of 1.5 percent per month, with a maturity date set for October 31, 2024. Sedermera Corporate Finance AB acted as the financial advisor for this transaction.MarketScreenerPHI secures a loan facility of in total SEK 7 millionPhase Holographic Imaging (PHI) has secured a loan facility totaling SEK 7 million from Bizcap AB, drawing an initial tranche of SEK 4.5 million to provide working capital. The loan carries a setup fee of 5 percent and an interest rate of 1.5 percent per month, with a maturity date set for October 31, 2024. Sedermera Corporate Finance AB acted as the financial advisor for this financing arrangement.PhiabPHI secures a loan facility of in total SEK 7 millionPhase Holographic Imaging (PHI) secured a loan facility of SEK 7 million from Bizcap AB, immediately drawing the first tranche of SEK 4.5 million to provide working capital. The agreement includes a 5 percent setup fee and an interest rate of 1.5 percent per month, with a maturity date of October 31, 2024. Sedermera Corporate Finance AB acted as the financial advisor for this financing arrangement.